Redeye provides a research update following the Q2 2024 report from Kancera.
Redeye provides an update following CLS’ Q2 report that fairly aligned with our expectations and did...
Redeye makes upward estimate revisions on the back of I-Tech’s solid Q2 figures.
Redeye states AVTECH’s report was in line with Redeye Research estimate (RRe) on net sales and a sol...
Q2 sales were in line, EBITDA 11% better Continues to scale well; sales +17%, opex +3% y-o-y Trading...
Small Q2 beat amid solid underlying performance In strong position to act on opportunities Fair valu...
Luxbright AB (”Luxbright” eller ”Bolaget”) har publicerat Bolagets delårsrapport för det första halv...
Refine Group (”Refine”, ”koncernen” eller ”bolaget”) publicerade den 23 augusti 2024 bolagets delårs...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har publicerat Koncernens delår...
I en utmanande omgivning tar New Wave marknadsandelar och ökar nu marknadssatsningarna.
Redeye regards BrightBid’s Q2 as a mixed-bag quarter, where the substantial cost cuts are the positi...
Lyckegård Group AB (”Lyckegård” eller ”Bolaget”) består fr.
Loihde reports its H1 results on August 27th. We expect slight net sales growth and a clear y/y prof...
Solteq is set to start showing clearly improved profitability figures, with the toughest actions now...
Redeye returns with an updated view of Egetis Therapeutics following the Q2 report and recent events...
Redeye states the report was weak, and it is apparent that InfraCom struggles with its Connect acqui...
Tumorad-01 is progressing towards the DMC meeting and the study is about to expand the number of pat...
Redeye provides an initial comment on the Q2 2024 report from Kancera, which showed lower operating ...
CirChem (”CirChem” eller ”Bolaget”) har nyligen stängt böckerna för Q2-24, ett kvartal präglat av fo...
Redeye comments on I-Tech’s Q2 figures that were stronger than our expectations in all regards.
